Amarin (AMRN) Competitors $14.67 +0.40 (+2.82%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. MRVI, COLL, MLTX, CALT, and MPLTShould you buy Amarin stock or one of its competitors? MarketBeat compares Amarin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amarin include Maravai LifeSciences (MRVI), Collegium Pharmaceutical (COLL), MoonLake Immunotherapeutics (MLTX), Calliditas Therapeutics AB (publ) (CALT), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry. AMRN vs. MRVIAMRN vs. COLLAMRN vs. MLTXAMRN vs. CALTAMRN vs. MPLTHow does Amarin compare to Maravai LifeSciences?Maravai LifeSciences (NASDAQ:MRVI) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment. Does the media prefer MRVI or AMRN? In the previous week, Maravai LifeSciences had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Maravai LifeSciences and 2 mentions for Amarin. Maravai LifeSciences' average media sentiment score of 0.48 beat Amarin's score of -1.00 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Is MRVI or AMRN more profitable? Amarin has a net margin of -15.51% compared to Maravai LifeSciences' net margin of -51.07%. Amarin's return on equity of -2.99% beat Maravai LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-51.07% -17.87% -9.08% Amarin -15.51%-2.99%-2.07% Which has stronger earnings & valuation, MRVI or AMRN? Amarin has higher revenue and earnings than Maravai LifeSciences. Amarin is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$185.74M6.10-$130.77M-$0.71N/AAmarin$216.76M1.42-$38.80M-$0.65N/A Which has more volatility & risk, MRVI or AMRN? Maravai LifeSciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Do analysts rate MRVI or AMRN? Maravai LifeSciences presently has a consensus target price of $5.50, suggesting a potential upside of 25.43%. Amarin has a consensus target price of $12.00, suggesting a potential downside of 18.21%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Do insiders & institutionals hold more shares of MRVI or AMRN? 50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryMaravai LifeSciences and Amarin tied by winning 8 of the 16 factors compared between the two stocks.How does Amarin compare to Collegium Pharmaceutical?Amarin (NASDAQ:AMRN) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Which has more risk and volatility, AMRN or COLL? Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Do analysts prefer AMRN or COLL? Amarin currently has a consensus target price of $12.00, indicating a potential downside of 18.21%. Collegium Pharmaceutical has a consensus target price of $57.50, indicating a potential upside of 66.32%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable earnings & valuation, AMRN or COLL? Collegium Pharmaceutical has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$216.76M1.42-$38.80M-$0.65N/ACollegium Pharmaceutical$780.57M1.44$62.87M$2.0416.95 Does the media refer more to AMRN or COLL? In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Amarin. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 2 mentions for Amarin. Collegium Pharmaceutical's average media sentiment score of 0.02 beat Amarin's score of -1.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is AMRN or COLL more profitable? Collegium Pharmaceutical has a net margin of 9.41% compared to Amarin's net margin of -15.51%. Collegium Pharmaceutical's return on equity of 95.18% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-15.51% -2.99% -2.07% Collegium Pharmaceutical 9.41%95.18%16.39% Do institutionals & insiders hold more shares of AMRN or COLL? 22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCollegium Pharmaceutical beats Amarin on 13 of the 16 factors compared between the two stocks.How does Amarin compare to MoonLake Immunotherapeutics?Amarin (NASDAQ:AMRN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability. Which has more volatility and risk, AMRN or MLTX? Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Which has stronger valuation & earnings, AMRN or MLTX? Amarin has higher revenue and earnings than MoonLake Immunotherapeutics. Amarin is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$216.76M1.42-$38.80M-$0.65N/AMoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.87N/A Do insiders & institutionals hold more shares of AMRN or MLTX? 22.3% of Amarin shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to AMRN or MLTX? In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 2 mentions for Amarin. MoonLake Immunotherapeutics' average media sentiment score of 0.45 beat Amarin's score of -1.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer AMRN or MLTX? Amarin presently has a consensus price target of $12.00, indicating a potential downside of 18.21%. MoonLake Immunotherapeutics has a consensus price target of $23.85, indicating a potential upside of 30.99%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.38 Is AMRN or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-15.51% -2.99% -2.07% MoonLake Immunotherapeutics N/A -85.15%-60.52% SummaryMoonLake Immunotherapeutics beats Amarin on 10 of the 15 factors compared between the two stocks.How does Amarin compare to Calliditas Therapeutics AB (publ)?Amarin (NASDAQ:AMRN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Do analysts prefer AMRN or CALT? Amarin currently has a consensus target price of $12.00, indicating a potential downside of 18.21%. Given Amarin's stronger consensus rating and higher possible upside, equities analysts plainly believe Amarin is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, AMRN or CALT? Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Do insiders and institutionals hold more shares of AMRN or CALT? 22.3% of Amarin shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to AMRN or CALT? In the previous week, Amarin had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Amarin and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Amarin's score of -1.00 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media. Company Overall Sentiment Amarin Negative Calliditas Therapeutics AB (publ) Neutral Is AMRN or CALT more profitable? Amarin has a net margin of -15.51% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Amarin's return on equity of -2.99% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Amarin-15.51% -2.99% -2.07% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has higher valuation and earnings, AMRN or CALT? Amarin has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Amarin is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$216.76M1.42-$38.80M-$0.65N/ACalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A SummaryAmarin beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.How does Amarin compare to Maplight Therapeutics?Maplight Therapeutics (NASDAQ:MPLT) and Amarin (NASDAQ:AMRN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings. Is MPLT or AMRN more profitable? Maplight Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Maplight Therapeutics' return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Maplight TherapeuticsN/A N/A N/A Amarin -15.51%-2.99%-2.07% Do analysts prefer MPLT or AMRN? Maplight Therapeutics presently has a consensus price target of $35.50, indicating a potential upside of 25.15%. Amarin has a consensus price target of $12.00, indicating a potential downside of 18.21%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Maplight Therapeutics is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maplight Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33 Which has preferable earnings & valuation, MPLT or AMRN? Amarin has higher revenue and earnings than Maplight Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaplight TherapeuticsN/AN/A-$161.15M-$40.99N/AAmarin$216.76M1.42-$38.80M-$0.65N/A Does the media prefer MPLT or AMRN? In the previous week, Maplight Therapeutics had 16 more articles in the media than Amarin. MarketBeat recorded 18 mentions for Maplight Therapeutics and 2 mentions for Amarin. Maplight Therapeutics' average media sentiment score of 0.08 beat Amarin's score of -1.00 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders & institutionals hold more shares of MPLT or AMRN? 22.3% of Amarin shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryMaplight Therapeutics beats Amarin on 10 of the 15 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition ExportMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$306.04M$3.33B$6.30B$12.21BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-22.4518.7220.7925.32Price / Sales1.42274.99518.7971.95Price / Cash38.92125.3543.1855.00Price / Book0.686.829.966.97Net Income-$38.80M$24.18M$3.54B$334.92M7 Day Performance-0.73%-0.32%-0.19%-0.98%1 Month Performance1.12%-1.41%-0.63%0.43%1 Year Performance33.62%61.67%34.10%33.61% Amarin Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.5546 of 5 stars$14.67+2.8%$12.00-18.2%+28.4%$306.04M$216.76MN/A360Negative NewsAnalyst DowngradeMRVIMaravai LifeSciences3.1828 of 5 stars$4.74-2.3%$5.70+20.3%+84.6%$1.25B$185.74MN/A610COLLCollegium Pharmaceutical2.7708 of 5 stars$35.81-5.3%$57.50+60.6%+14.2%$1.23B$780.57M17.55210MLTXMoonLake Immunotherapeutics3.438 of 5 stars$18.84+10.4%$23.46+24.5%-57.7%$1.22BN/AN/A2News CoverageHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60BN/A180 Related Companies and Tools Related Companies Maravai LifeSciences Alternatives Collegium Pharmaceutical Alternatives MoonLake Immunotherapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Maplight Therapeutics Alternatives Xeris Biopharma Alternatives DBV Technologies Alternatives Evotec Alternatives Septerna Alternatives Savara Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
